ROCHESTER, N.Y.--(BUSINESS WIRE)--Biophan Technologies, Inc. (OTCBB: BIPH; FWB: BTN), a developer of next-generation biomedical technology, in conjunction with MYOTECH, LLC, recently presented results of animal studies that indicate the potential of the MYO-VAD cardiac support system to significantly improve the treatment of heart failure. This devastating disease currently has no cure and affects an estimated 5,000,000 Americans each year.
